|
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
|
32130059
|
J Clin Oncol
|
|
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
|
18550118
|
J. Urol.
|
|
A <i>K</i>-fold Averaging Cross-validation Procedure.
|
27630515
|
J Nonparametr Stat
|
|
A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.
|
28482112
|
Biometrics
|
|
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
|
12925511
|
Biostatistics
|
|
A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
|
31376183
|
Prostate
|
|
A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas.
|
27992432
|
PLoS One
|
|
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.
|
23232570
|
Adv Anat Pathol
|
|
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
|
19435894
|
Cancer Res.
|
|
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
|
18056174
|
Clin. Cancer Res.
|
|
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
|
18316555
|
Clin. Cancer Res.
|
|
A new family-based association test via a least-squares method.
|
16451567
|
BMC Genet.
|
|
A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies.
|
19459841
|
Biometrics
|
|
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
|
28376184
|
J Natl Cancer Inst
|
|
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
|
30137376
|
J. Natl. Cancer Inst.
|
|
A practical multifaceted approach to selecting differentially expressed genes.
|
19455259
|
Cancer Inform
|
|
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
|
20447916
|
Cancer Epidemiol. Biomarkers Prev.
|
|
A regularized multivariate regression approach for eQTL analysis.
|
26085849
|
Stat Biosci
|
|
A sparse Ising model with covariates.
|
25099186
|
Biometrics
|
|
A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data.
|
27276420
|
Biometrics
|
|
A two-stage approach for dynamic prediction of time-to-event distributions.
|
26748812
|
Stat Med
|
|
A web-based system for managing and co-ordinating multiple multisite studies.
|
16279578
|
Clin Trials
|
|
Accommodating Covariates in ROC Analysis.
|
20046933
|
Stata J
|
|
Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
|
19322904
|
Int. J. Cancer
|
|
Adding Rigor to Biomarker Evaluations-EDRN Experience.
|
33172885
|
Cancer Epidemiol Biomarkers Prev
|
|
Addressing patient heterogeneity in disease predictive model development.
|
34184256
|
Biometrics
|
|
Addressing patient heterogeneity in disease predictive model development.
|
34184256
|
Biometrics
|
|
Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve.
|
22822245
|
Biometrika
|
|
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting.
|
18477651
|
Am. J. Epidemiol.
|
|
Adopting nested case-control quota sampling designs for the evaluation of risk markers.
|
23807695
|
Lifetime Data Anal
|
|
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
|
19362088
|
Gastroenterology
|
|
An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers.
|
14615632
|
J. Biomed. Biotechnol.
|
|
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies.
|
24807840
|
J. Proteome Res.
|
|
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
|
17981926
|
Clin. Chem.
|
|
Analyzing LC-MS/MS data by spectral count and ion abundance: two case studies.
|
24163717
|
Stat Interface
|
|
Application of a methylation gene panel by quantitative PCR for lung cancers.
|
16644104
|
Cancer Lett.
|
|
Application of Multidimensional Selective Item Response Regression Model for Studying Multiple Gene Methylation in SV40 Oncogenic Pathways.
|
19830254
|
J Am Stat Assoc
|
|
Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers.
|
16542256
|
Biometrics
|
|
Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation.
|
16443924
|
Biostatistics
|
|
Assessing accuracy of mammography in the presence of verification bias and intrareader correlation.
|
15737102
|
Biometrics
|
|
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
|
16622122
|
J. Natl. Cancer Inst.
|
|
Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods.
|
20527013
|
Stat Med
|
|
Assessing the diagnostic accuracy of a sequence of tests.
|
12925502
|
Biostatistics
|
|
Assessing the incremental value of new biomarkers based on OR rules.
|
30590454
|
Biostatistics
|
|
Assessing the value of risk predictions by using risk stratification tables.
|
19017593
|
Ann. Intern. Med.
|
|
Assessing treatment-selection markers using a potential outcomes framework.
|
22299708
|
Biometrics
|
|
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
|
30003238
|
JAMA Oncol
|
|
Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
|
28520829
|
JAMA Oncol
|
|
Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.
|
14504198
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Association of serum phospholipid fatty acids with breast cancer risk among postmenopausal cigarette smokers.
|
19255861
|
Cancer Causes Control
|
|
Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling.
|
24039313
|
Ann Stat
|
|
Bayesian inference of hub nodes across multiple networks.
|
30051914
|
Biometrics
|
|
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies.
|
18310059
|
Biostatistics
|
|
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies.
|
18310059
|
Biostatistics
|
|
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies.
|
18310059
|
Biostatistics
|
|
Biases introduced by choosing controls to match risk factors of cases in biomarker research.
|
22730452
|
Clin. Chem.
|
|
Biomarker evaluation and comparison using the controls as a reference population.
|
18755739
|
Biostatistics
|
|
Biomarker-based methods for determining noncompliance in a prevention trial.
|
12505245
|
Control Clin Trials
|
|
Biomarker-based methods for determining noncompliance in a prevention trial.
|
12505245
|
Control Clin Trials
|
|
Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.
|
32532830
|
Cancer Epidemiol Biomarkers Prev
|
|
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
|
34995129
|
J Clin Oncol
|
|
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
|
12324514
|
Clin. Chem.
|
|
Boosting with missing predictors.
|
19948743
|
Biostatistics
|
|
BOOTSTRAP INFERENCE FOR NETWORK CONSTRUCTION WITH AN APPLICATION TO A BREAST CANCER MICROARRAY STUDY.
|
24563684
|
Ann Appl Stat
|
|
Borrowing Information across Populations in Estimating Positive and Negative Predictive Values.
|
22021938
|
J R Stat Soc Ser C Appl Stat
|
|
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
|
25385735
|
J. Clin. Oncol.
|
|
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.
|
19758683
|
Urology
|
|
Cancer Biomarkers and Big Data: A Planetary Science Approach.
|
32976775
|
Cancer Cell
|
|
Cancer Biomarkers and Big Data: A Planetary Science Approach.
|
32976775
|
Cancer Cell
|
|
Characterizing expected benefits of biomarkers in treatment selection.
|
25190512
|
Biostatistics
|
|
Characterizing expected benefits of biomarkers in treatment selection.
|
25190512
|
Biostatistics
|
|
Classification versus association models: should the same methods apply?
|
20515278
|
Scand. J. Clin. Lab. Invest. Suppl.
|
|
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
|
15741570
|
J. Natl. Cancer Inst.
|
|
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.
|
19058137
|
Prostate
|
|
Combining biomarkers linearly and nonlinearly for classification using the area under the ROC curve.
|
27058981
|
Stat Med
|
|
Combining biomarkers to detect disease with application to prostate cancer.
|
14557109
|
Biostatistics
|
|
Combining multiple biomarkers linearly to maximize the partial area under the ROC curve.
|
29082535
|
Stat Med
|
|
Combining predictors for classification using the area under the receiver operating characteristic curve.
|
16542249
|
Biometrics
|
|
Combining results of microarray experiments: a rank aggregation approach.
|
17049026
|
Stat Appl Genet Mol Biol
|
|
Combining several screening tests: optimality of the risk score.
|
12230001
|
Biometrics
|
|
Commentary: Reporting standards are needed for evaluations of risk reclassification.
|
21571811
|
Int J Epidemiol
|
|
Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
|
17671958
|
Stat Med
|
|
Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs.
|
16895044
|
Clin Trials
|
|
Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs.
|
16895044
|
Clin Trials
|
|
Comparison of two correlated ROC surfaces at a given pair of true classification rates.
|
30010205
|
Stat Med
|
|
Comparison of two correlated ROC curves at a given specificity or sensitivity level.
|
27324068
|
Stat Med
|
|
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.
|
22238117
|
Stat Med
|
|
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility.
|
19097251
|
Stat Med
|
|
Constructing dynamic treatment regimes with shared parameters for censored data.
|
31951041
|
Stat Med
|
|
Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
|
25471344
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
|
30076904
|
J Urol
|
|
Contrasting two frameworks for ROC analysis of ordinal ratings.
|
20147599
|
Med Decis Making
|
|
Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
|
33137463
|
J Thorac Oncol
|
|
Copy number alterations are associated with metastatic-lethal progression in prostate cancer.
|
32071439
|
Prostate Cancer Prostatic Dis
|
|
Cruciferous vegetable supplementation in a controlled diet study alters the serum peptidome in a GSTM1-genotype dependent manner.
|
21272319
|
Nutr J
|
|
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data.
|
12762451
|
Biometrics
|
|
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.
|
26431551
|
PLoS One
|
|
Design and estimation for evaluating principal surrogate markers in vaccine trials.
|
23409839
|
Biometrics
|
|
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study.
|
30699099
|
Am J Gastroenterol
|
|
Detecting genomic aberrations using products in a multiscale analysis.
|
19817738
|
Biometrics
|
|
Development of common data elements: the experience of and recommendations from the early detection research network.
|
12706181
|
Int J Med Inform
|
|
Diagnostic markers for early detection of ovarian cancer.
|
18258665
|
Clin. Cancer Res.
|
|
Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors.
|
15580314
|
Oncogene
|
|
Distribution-free ROC analysis using binary regression techniques.
|
12933607
|
Biostatistics
|
|
DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.
|
32226005
|
PLoS Genet
|
|
DNA methylation profiles in African American prostate cancer patients in relation to disease progression.
|
26902887
|
Genomics
|
|
Does the net reclassification improvement help us evaluate models and markers?
|
24592500
|
Ann. Intern. Med.
|
|
Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma.
|
34954100
|
Contemp Clin Trials
|
|
Efficient use of longitudinal CD4 counts and viral load measures in survival analysis.
|
22415871
|
Stat Med
|
|
Epidemiologic methods developments: a look forward to the year 2032.
|
17855116
|
Ann Epidemiol
|
|
Epidemiology informing clinical practice: from bills of mortality to population laboratories.
|
16341118
|
Nat Clin Pract Oncol
|
|
Estimating improvement in prediction with matched case-control designs.
|
23358916
|
Lifetime Data Anal
|
|
Estimating Risk with Time-to-Event Data: An Application to the Women's Health Initiative.
|
25018574
|
J Am Stat Assoc
|
|
Estimating the capacity for improvement in risk prediction with a marker.
|
18714084
|
Biostatistics
|
|
Estimating the diagnostic likelihood ratio of a continuous marker.
|
20639522
|
Biostatistics
|
|
Estimating the receiver operating characteristic curve in studies that match controls to cases on covariates.
|
23601953
|
Acad Radiol
|
|
Estimation and Comparison of Receiver Operating Characteristic Curves.
|
20161343
|
Stata J
|
|
Evaluating a New Cancer Screening Blood Test: Unintended Consequences and the Need for Clarity in Policy Making.
|
32761203
|
J Natl Cancer Inst
|
|
Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies.
|
26883772
|
Biostatistics
|
|
Evaluating classification performance of biomarkers in two-phase case-control studies.
|
30209824
|
Stat Med
|
|
Evaluating incremental values from new predictors with net reclassification improvement in survival analysis.
|
23254468
|
Lifetime Data Anal
|
|
Evaluating longitudinal markers under two-phase study designs.
|
29912281
|
Biostatistics
|
|
Evaluating markers for selecting a patient's treatment.
|
15606407
|
Biometrics
|
|
Evaluating prognostic accuracy of biomarkers in nested case-control studies.
|
21856652
|
Biostatistics
|
|
Evaluating prognostic accuracy of biomarkers under competing risk.
|
22150576
|
Biometrics
|
|
Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
|
29301497
|
BMC Med Res Methodol
|
|
Evaluating technologies for classification and prediction in medicine.
|
16320261
|
Stat Med
|
|
Evaluating the predictive value of biomarkers with stratified case-cohort design.
|
23173848
|
Biometrics
|
|
Evaluating the predictiveness of a continuous marker.
|
17489968
|
Biometrics
|
|
Evaluating the ROC performance of markers for future events.
|
18064569
|
Lifetime Data Anal
|
|
Evaluation of matrix-assisted laser desorption/ionization-time of flight mass spectrometry proteomic profiling: identification of alpha 2-HS glycoprotein B-chain as a biomarker of diet.
|
15841498
|
Proteomics
|
|
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
|
15613711
|
Clin. Chem.
|
|
Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.
|
30651550
|
Nat Commun
|
|
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model.
|
12807723
|
Carcinogenesis
|
|
Factors influencing serum CA125II levels in healthy postmenopausal women.
|
11352859
|
Cancer Epidemiol. Biomarkers Prev.
|
|
FDR-controlling testing procedures and sample size determination for microarrays.
|
15977294
|
Stat Med
|
|
Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context.
|
22875756
|
Am. J. Epidemiol.
|
|
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
|
30464023
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer.
|
18612128
|
J. Natl. Cancer Inst.
|
|
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
|
19064562
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.
|
20800559
|
Mol Oncol
|
|
Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.
|
17624589
|
Breast Cancer Res. Treat.
|
|
Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
|
25733690
|
Mol Cell Proteomics
|
|
Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.
|
26998508
|
Cell Mol Gastroenterol Hepatol
|
|
Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.
|
20395854
|
Ann. Surg.
|
|
Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.
|
26537180
|
Stat Med
|
|
Hybrid design evaluating new biomarkers when there is an existing screening test.
|
33540472
|
Stat Med
|
|
Identification of osteopontin as a novel marker for early hepatocellular carcinoma.
|
21953299
|
Hepatology
|
|
Identification of the optimal treatment regimen in the presence of missing covariates.
|
31774192
|
Stat Med
|
|
Identifying optimal biomarker combinations for treatment selection through randomized controlled trials.
|
25948620
|
Clin Trials
|
|
Identifying optimal biomarker combinations for treatment selection via a robust kernel method.
|
25124089
|
Biometrics
|
|
Identifying target populations for screening or not screening using logic regression.
|
15568185
|
Stat Med
|
|
Immunohistochemical validation of expression microarray results.
|
15858137
|
J Mol Diagn
|
|
Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.
|
26260109
|
Clin. Gastroenterol. Hepatol.
|
|
Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
|
28258053
|
Cancer Epidemiol Biomarkers Prev
|
|
Improving biomarker identification with better designs and reporting.
|
21666069
|
Clin. Chem.
|
|
IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS.
|
28943991
|
Ann Appl Stat
|
|
Improving risk classification of critical illness with biomarkers: a simulation study.
|
23566734
|
J Crit Care
|
|
Improving the quality of biomarker discovery research: the right samples and enough of them.
|
25837819
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
|
15824739
|
Oncogene
|
|
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
|
29422418
|
Eur Urol Focus
|
|
Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women.
|
22277732
|
Cancer Prev Res (Phila)
|
|
Insights into latent class analysis of diagnostic test performance.
|
17085745
|
Biostatistics
|
|
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and the risk of fibrocystic breast conditions among Chinese women.
|
16331609
|
Int. J. Cancer
|
|
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.
|
21653254
|
Mol. Cell Proteomics
|
|
Integrating the predictiveness of a marker with its performance as a classifier.
|
17982157
|
Am. J. Epidemiol.
|
|
Joint modeling, covariate adjustment, and interaction: contrasting notions in risk prediction models and risk prediction performance.
|
21968770
|
Epidemiology
|
|
Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint.
|
31833561
|
Biometrics
|
|
Letter by Pepe et al regarding article, "Use and misuse of the receiver operating characteristic curve in risk prediction".
|
17679623
|
Circulation
|
|
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.
|
15105181
|
Am. J. Epidemiol.
|
|
LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS.
|
24204441
|
Ann Appl Stat
|
|
LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS.
|
24204441
|
Ann Appl Stat
|
|
Low Prevalence of Screen-Detected Colorectal Cancer in an Average-Risk Population: The New Normal.
|
34547437
|
Clin Gastroenterol Hepatol
|
|
Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability.
|
22412972
|
PLoS ONE
|
|
MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.
|
26342024
|
Cancer Prev Res (Phila)
|
|
Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value.
|
17501939
|
Biometrics
|
|
Measures to summarize and compare the predictive capacity of markers.
|
20224632
|
Int J Biostat
|
|
Measuring the performance of markers for guiding treatment decisions.
|
21320940
|
Ann. Intern. Med.
|
|
Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.
|
20054437
|
Stat Biopharm Res
|
|
Model checking for ROC regression analysis.
|
17447940
|
Biometrics
|
|
Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes.
|
29775599
|
Gastroenterology
|
|
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.
|
18483343
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Net risk reclassification p values: valid or misleading?
|
24681599
|
J. Natl. Cancer Inst.
|
|
New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization.
|
24124229
|
Cancer Discov
|
|
Nidogen-2: a new serum biomarker for ovarian cancer.
|
19883638
|
Clin. Biochem.
|
|
Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs.
|
30555194
|
J Am Stat Assoc
|
|
Observational studies, clinical trials, and the women's health initiative.
|
17943443
|
Lifetime Data Anal
|
|
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.
|
18794547
|
J. Clin. Oncol.
|
|
On longitudinal prediction with time-to-event outcome: Comparison of modeling options.
|
27438160
|
Biometrics
|
|
Optimized normalization for antibody microarrays and application to serum-protein profiling.
|
15793073
|
Mol. Cell Proteomics
|
|
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
|
26327354
|
J Urol
|
|
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
|
21372036
|
Cancer Prev Res (Phila)
|
|
Partial AUC estimation and regression.
|
14601762
|
Biometrics
|
|
Partially supervised learning using an EM-boosting algorithm.
|
15032790
|
Biometrics
|
|
Partly conditional survival models for longitudinal data.
|
16011684
|
Biometrics
|
|
Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
|
18948370
|
Clin. Chem.
|
|
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
|
30664734
|
Prostate Cancer Prostatic Dis.
|
|
Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective.
|
27446505
|
Stat Biosci
|
|
Personalized Integrated Network Modeling of the Cancer Proteome Atlas.
|
30297783
|
Sci Rep
|
|
Phases of biomarker development for early detection of cancer.
|
11459866
|
J. Natl. Cancer Inst.
|
|
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.
|
18840817
|
J. Natl. Cancer Inst.
|
|
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
|
26549697
|
Sci Rep
|
|
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
|
33893071
|
Cancer Prev Res (Phila)
|
|
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
|
33893071
|
Cancer Prev Res (Phila)
|
|
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.
|
18483327
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis.
|
16921513
|
Prostate
|
|
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
|
17455987
|
PLoS Med.
|
|
Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
|
12483774
|
Stat Med
|
|
Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
|
12483774
|
Stat Med
|
|
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
|
18766180
|
Br. J. Cancer
|
|
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
|
20875091
|
BJU Int.
|
|
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
|
20875091
|
BJU Int.
|
|
Presence of simian virus 40 DNA sequences in human lymphomas.
|
11897287
|
Lancet
|
|
Prevalidation of salivary biomarkers for oral cancer detection.
|
22301830
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Pro-surfactant protein B as a biomarker for lung cancer prediction.
|
24248694
|
J. Clin. Oncol.
|
|
Problems with risk reclassification methods for evaluating prediction models.
|
21555714
|
Am. J. Epidemiol.
|
|
Prospective accuracy for longitudinal markers.
|
17688486
|
Biometrics
|
|
Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.
|
19836772
|
J. Urol.
|
|
Quantifying and comparing the predictive accuracy of continuous prognostic factors for binary outcomes.
|
14744831
|
Biostatistics
|
|
Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome.
|
15122736
|
Stat Med
|
|
Quantifying peptide signal in MALDI-TOF mass spectrometry data.
|
16195224
|
Mol. Cell Proteomics
|
|
Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network.
|
30439517
|
Contemp Clin Trials
|
|
Re: "Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study".
|
23524037
|
Am. J. Epidemiol.
|
|
Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values.
|
30099328
|
Cancer Epidemiol
|
|
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
|
29433975
|
Eur. Urol.
|
|
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues.
|
16944874
|
Anal. Chem.
|
|
Resampling Procedures for Making Inference under Nested Case-control Studies.
|
24436503
|
J Am Stat Assoc
|
|
Response.
|
25432412
|
J. Natl. Cancer Inst.
|
|
Robust prediction of t-year survival with data from multiple studies.
|
20670303
|
Biometrics
|
|
Robust risk prediction with biomarkers under two-phase stratified cohort design.
|
27037494
|
Biometrics
|
|
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
|
29433973
|
Eur Urol
|
|
Sample size calculations for comparative studies of medical tests for detecting presence of disease.
|
11870820
|
Stat Med
|
|
Scale-based normalization of spectral data.
|
17192066
|
Cancer Biomark
|
|
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
|
18024530
|
Clin. Chem.
|
|
Selecting Biomarkers for building optimal treatment selection rules using Kernel Machines.
|
32921837
|
J R Stat Soc Ser C Appl Stat
|
|
Selecting differentially expressed genes from microarray experiments.
|
12762450
|
Biometrics
|
|
Semiparametric estimation of time-dependent ROC curves for longitudinal marker data.
|
15475423
|
Biostatistics
|
|
Semiparametric isotonic regression analysis for risk assessment under nested case-control and case-cohort designs.
|
31868119
|
Stat Methods Med Res
|
|
Semiparametric methods for evaluating the covariate-specific predictiveness of continuous markers in matched case-control studies.
|
21562626
|
J R Stat Soc Ser C Appl Stat
|
|
Semiparametric methods for evaluating risk prediction markers in case-control studies.
|
22822247
|
Biometrika
|
|
Semiparametric models of time-dependent predictive values of prognostic biomarkers.
|
19397579
|
Biometrics
|
|
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
|
28376157
|
J Natl Cancer Inst
|
|
Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.
|
26813970
|
Cancer Prev Res (Phila)
|
|
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
|
12097261
|
Cancer Res.
|
|
Signal detection in high-resolution mass spectrometry data.
|
18173224
|
J. Proteome Res.
|
|
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.
|
12455028
|
Int. J. Cancer
|
|
Standardizing diagnostic markers to evaluate and compare their performance.
|
16135934
|
Epidemiology
|
|
Statistical Aspects of the Use of Biomarkers in Nutritional Epidemiology Research.
|
19841649
|
Stat Biosci
|
|
Statistical considerations in combining biomarkers for disease classification.
|
15322313
|
Dis. Markers
|
|
Statistical inference for net benefit measures in biomarker validation studies.
|
31732971
|
Biometrics
|
|
Statistical issues in the evaluation of screening and early detection modalities.
|
18452826
|
Urol. Oncol.
|
|
Statistical Methods for Tissue Array Images - Algorithmic Scoring and Co-training.
|
22984376
|
Ann Appl Stat
|
|
Strategies for validating biomarkers using data from a reference set.
|
31420985
|
Biostatistics
|
|
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration.
|
21414753
|
J Clin Epidemiol
|
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
21434890
|
Eur. J. Clin. Invest.
|
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
21424820
|
Eur. J. Epidemiol.
|
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
21407270
|
Eur. J. Hum. Genet.
|
|
Structured penalties for functional linear models-partially empirical eigenvectors for regression.
|
22639702
|
Electron J Stat
|
|
Survival model predictive accuracy and ROC curves.
|
15737082
|
Biometrics
|
|
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
|
32852532
|
JAMA Oncol
|
|
Telomere length in the colon declines with age: a relation to colorectal cancer?
|
16537718
|
Cancer Epidemiol. Biomarkers Prev.
|
|
Testing for improvement in prediction model performance.
|
23296397
|
Stat Med
|
|
The analysis of placement values for evaluating discriminatory measures.
|
15180681
|
Biometrics
|
|
The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.
|
26712941
|
Cancer Prev Res (Phila)
|
|
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers.
|
23193062
|
Clin. Chem.
|
|
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
|
23313212
|
J. Urol.
|
|
The joint graphical lasso for inverse covariance estimation across multiple classes.
|
24817823
|
J R Stat Soc Series B Stat Methodol
|
|
The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves.
|
33530129
|
Stat Med
|
|
The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker.
|
16428259
|
Biostatistics
|
|
The potential of genes and other markers to inform about risk.
|
20160267
|
Cancer Epidemiol. Biomarkers Prev.
|
|
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting.
|
22552047
|
Urol. Oncol.
|
|
The sensitivity and specificity of markers for event times.
|
16079162
|
Biostatistics
|
|
The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.
|
19367279
|
Br. J. Cancer
|
|
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
|
18382671
|
PLoS ONE
|
|
Time-dependent Predictive Values of Prognostic Biomarkers with Failure Time Outcome.
|
19655041
|
J Am Stat Assoc
|
|
Tree-based Ensemble Methods For Individualized Treatment Rules.
|
31650095
|
Biostat Epidemiol
|
|
Two-stage biomarker panel study and estimation allowing early termination for futility.
|
25964662
|
Biostatistics
|
|
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage.
|
18519043
|
Gastroenterology
|
|
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation.
|
21363920
|
Cancer Res.
|
|
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.
|
32722209
|
Cancers (Basel)
|
|
Ultrasensitive detection and characterization of posttranslational modifications using surface-enhanced Raman spectroscopy.
|
16737206
|
Anal. Chem.
|
|
Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design.
|
26845527
|
Biometrics
|
|
Updating risk prediction tools: a case study in prostate cancer.
|
22095849
|
Biom J
|
|
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
|
23515404
|
Clin. Cancer Res.
|
|
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
|
33080150
|
J Urol
|
|
Using the ROC curve for gauging treatment effect in clinical trials.
|
16220481
|
Stat Med
|
|
Validation of a novel model for the early detection of hepatocellular carcinoma.
|
30675135
|
Clin Proteomics
|
|
Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.
|
30557738
|
Clin Gastroenterol Hepatol
|
|
Vitamin D receptor gene polymorphisms and prostate cancer risk.
|
15065089
|
Prostate
|
|
When does combining markers improve classification performance and what are implications for practice?
|
23348801
|
Stat Med
|
